Table 5.
TKI | Ingredients | Particle Size | Tested Human Cancer Cell Lines | Benefits | Refs. |
---|---|---|---|---|---|
erlotinib | Precirol®, Miglyol®, poloxamer 407 | ca. 109 nm | lung adenocarcinoma A549 cells | ↑ cellular uptake apoptosis induction ↑ anticancer effect |
[225] |
gefitinib + paclitaxel | trilaurin, α-tocopherol, 1,2-distearoyl-sn-glycero-3-phosphocholine, (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000], luteinizing hormone release hormone | 100–300 nm | lung adenocarcinoma A549, H-1975, PC-9, PC-9GR cells | ↑ anticancer effect | [226] |
imatinib | Compritol® ATO 888, oleic acid, Gelucire® 48/16, Gelucire® 43/01, Span 80, Tween® 80 | ca. 96 nm | gastric adenocarcinoma CRL-1739 cells | sustained release ↑ anticancer effect |
[227] |
imatinib | stearic acid, sesame oil, sodium lauryl sulphate, Tween® 80 | ca. 104 nm | MCF-7 breast cancer cells | ↑ anticancer effect | [228] |
sorafenib | tripalmitin, Captex® 355 EP/NF | <300 nm | hepatocellular carcinoma HepG2, Hep3B, Huh7, PLC/PRF/5 cells | sustained release ↑ cellular uptake ↑ anticancer effect |
[229] |
sunitinib | Pluronic® F127, cholesterol, Labrafac™, biotin, stearylamine | ca. 125 nm | lung adenocarcinoma A549 cells | sustained release (>8 h) ↑ cellular uptake ↑ anticancer effect |
[230] |
osimertinib | stearic acid, Labrafil® M 1944CS, poloxamer 407 | ca. 162 nm | lung adenocarcinoma A549 cells | sustained release ↑ permeation ↑ anticancer effect |
[231] |